This is an excerpt from The Essential Guide to CBD by the Editors at Reader’s Digest and Project CBD.
Leading researchers at U.S. National Institutes of Health (NIH) recognize the importance of the endocannabinoid system as a crucial fulcrum of health. This is emphasized in a 2013 report by NIH scientists Pal Pacher and George Kunos, who maintain that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans.”1
Much depends on how the two cannabinoid receptor subtypes – CB1 and CB2 – function. In both the liver and kidneys (and other) internal organs, the CB1and CB2 receptors have a yin-yang type of relationship. When the CB1 receptor is overstimulated and there’s not enough CB2 receptor signaling, or vice versa, various diseases follow.2
Chronic liver disease is a major public health problem affecting hundreds of millions of people throughout the world. Fatty liver, kidney disease, diabetes, and other diet-related metabolic disorders are expressions of overactive CB1 receptor signaling and inadequate CB2 receptor stimulation. CBD fine-tunes the endocannabinoid system by turning down the CB1 dimmer switch while mimicking and augmenting CB2 activity.
In the liver and kidneys specifically, CB1 signaling is profibrotic, meaning it encourages the development of fibrous connective tissue in response to injury or damage. CB2 signaling is antifibrotic, meaning it impedes fibrosis and thins the blood. When CB1 and CB2 are out of balance, it can lead to fibrosis, or dangerous scarring on these organs. Cirrhosis of the liver and nonalcoholic liver disease are two serious conditions that are marked by too much fibrosis, which is also a characteristic of chronic kidney disease.
Effective treatment strategies for fibrotic conditions should aim to boost CB2 signaling, while fine-tuning CB1 in the other direction. That’s what CBD does, and that’s how CBD may help to fend off disease and keep your liver and kidneys healthy.3 4
CBD’s ability to protect the liver was the focus of a 2017 study published in the journal Scientific Reports, which examined the effect of CBD on mice that had been given enough ethanol to mimic chronic and binge alcohol use. The study found that CBD oil minimized fat accumulation and damage to the liver. The authors concluded: “CBD may have therapeutic potential in the treatment of alcoholic liver diseases associated with inflammation, oxidative stress and steatosis [fatty change], which deserves exploration in human trials.”5
In another study that examined the impact of CBD on liver health in animals, researchers gave lab rats CBD and other cannabinoids for eight months. Published in Cell Death and Disease, the study found that CBD killed off hepatic stellate cells, which trigger scar tissue in the liver.6
“Not only does there not seem to be any evidence that CBD plays a role in damaging the liver over a long period of time,” the scientists reported, “it actually seems that the cannabinoid may help to improve liver health and reduce the effects of any damage done to it. More studies continue to be required, particularly those involving human participants. However, current evidence appears to support the notion that CBD oil use is not only safe, but it may even have a potentially therapeutic role in treating liver disease.”7
This assessment calls into question Food & Drug Administration warnings, based on weak evidence, that CBD may harm the liver.
An excerpt from The Essential Guide to CBD by the editors of Reader’s Digest & Project CBD.
Copyright, Project CBD. May not be reprinted without permission.
- Pál Pacher and George Kunos, “Modulating the Endocannabinoid System in Human Health and Disease: Successes and Failures,” FEBS Journal 280, no. 9 (May 2013): 1918–43.
- Ariane Mallat, Fatima Teixeira-Clerc, and Sophie Lotersztajn, “Cannabinoid Signaling and Liver Therapeutics,” Journal of Hepatology 59, no. 4 (October 2013): 891–96.
- Anna Parfieniuk and Robert Flisiak, “Role of Cannabinoids in Chronic Liver Diseases,” World Journal of Gastroenterology 14, 40 (October 28, 2008): 6109–14.
- Janice T. Chua et al., “Endocannabinoid System and the Kidneys: From Renal Physiology tocInjurycand Disease,” Cannabis and Cannabinoid Research 4, no. 1 (March 13, 2019): 10–20.
- Yuping Wang et al., “Cannabidiol Attenuates Alcohol-Induced Liver Steatosis, Metabolic Dysregulation, Inflammation and Neutrophil-Mediated Injury,” Scientific Reports 7, no. 1, (September 21, 2017): 12064.
- M.P. Lim, L.A. Devi, and R. Rozenfeld, “Cannabidiol Causes Activated Hepatic Stellate Cell Death Through a Mechanism of Endoplasmic Reticulum Stress-Induced Apoptosis,” Cell Death & Disease 2, no. 6 (June 9, 2011): e170.
- Lisa Rennie, “Can Using CBD Oil Cause Long-Term Damage to Your Liver,” CBD Health & Wellness (November 22, 2018).
Both milk thistle and cannabis convey therapeutic benefits that are mediated by the endocannabinoid system.
Pioneers in the field of CBD and cannabinoid science have opened the door to new vistas of understanding human biology and physiology.
The protective effect of cannabinoids for those living with Type 2 diabetes and obesity is particularly pronounced among people with schizophrenia. Why?
During the first week of July 2018, five-hundred-and-thirty-five delegates from five continents met at the University of Leiden in the Netherlands for the 28th annual symposium of the International Cannabinoid Research Society (ICRS). The four-day conference showcased recent scientific discoveries about cannabis components and various ways of targeting the endocannabinoid system to improve health outcomes.